We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Read MoreHide Full Article
Key Takeaways
Liquidia resolves six legal disputes with United Therapeutics, ensuring Yutrepia access for PAH patients.
Liquidia will pay $380.7 million in settlement obligations across 2026 and 2027.
Yutrepia posted $222.7 million in preliminary third-quarter sales as Liquidia advances L606.
Liquidia Corporation (LQDA - Free Report) has reached a global settlement with United Therapeutics (UTHR - Free Report) , resolving all six pending legal disputes between the companies and providing greater clarity on the commercial outlook for Yutrepia.
The agreement ensures uninterrupted access to Yutrepia for patients with pulmonary arterial hypertension (PAH).
The stock is trading up in pre-market trading.
Year to date, LQDA stock has lost 22.3% against the industry’s growth of 1.8%.
Image Source: Zacks Investment Research
However, the settlement comes at a substantial financial cost, with Liquidia agreeing to make net payments of $380.7 million in multiple installments during 2026-2027.
Although the agreement removes a significant source of legal uncertainty, the financial obligations and the removal of the pulmonary hypertension associated with interstitial lung disease (PH-ILD) indication from Yutrepia’s label present challenges for the company.
LQDA Settles All Pending Litigation With UTHR
The settlement follows a Sept. 30, 2026, ruling by the U.S. District Court for the District of Delaware, which found that claims 1 and 14 of UTHR’s U.S. Patent No. 11,826,327 were valid and infringed by Liquidia. The patent claims generally cover the treatment of PH-ILD with inhaled treprostinil, including dry-powder formulations.
Under the agreement, Liquidia has agreed not to appeal the ruling. It has also submitted a supplement to remove the PH-ILD indication from Yutrepia’s label and will discontinue promotion of the drug for this condition.
The settlement resolves six legal matters involving patent infringement, alleged trade secret misappropriation, breach of contract and antitrust violations. The agreement includes mutual releases and does not constitute an admission of liability by either company.
The resolution eliminates the need for Liquidia to continue allocating resources to these disputes, providing greater certainty as it focuses on commercial execution and clinical development.
However, the removal of the PH-ILD indication limits Yutrepia’s current labeled use to PAH, making continued growth in this market particularly important.
Financial Details of LQDA and UTHR Litigation Settlement
Under the settlement terms, Liquidia will make a net payment of $175 million to UTHR within 30 business days. The company will subsequently pay another $145.4 million in two equal installments of $72.7 million, due by Jan. 31, 2027, and April 30, 2027.
In connection with the settlement, Liquidia entered into agreements with the parties with interests in the antitrust litigation related to treprostinil Injection. As per the terms of the agreement, Liquidia will pay an aggregate of $60.3 million this month in full satisfaction of those parties’ interests in the antitrust litigation.
These amounts bring the total settlement-related payments to $380.7 million.
The sizable financial commitment could constrain Liquidia’s financial flexibility in the near term. Nevertheless, management expects to fund the obligations through Yutrepia sales and existing cash reserves while continuing to invest in the business.
LQDA Provides Preliminary Sales
Liquidia has entered the settlement with encouraging commercial momentum. Preliminary, unaudited third-quarter 2026 results showed Yutrepia net product sales of $222.7 million, contributing to cash and cash equivalents of $396.1 million as of Sept. 30, 2026.
Management expects to rebuild its cash position and fund planned clinical studies without requiring additional financing. However, the company's ability to meet its settlement obligations while preserving sufficient resources for commercial expansion and research will be an important factor to monitor.
Liquidia has also terminated its promotional agreement related to treprostinil injection and will no longer commercially support the product.
Pipeline Development Remains a Priority
Beyond Yutrepia, Liquidia plans to continue advancing L606, an investigational extended-release formulation of treprostinil administered twice daily through a next-generation nebulizer. Pivotal studies are planned to support its development for PAH and PH-ILD.
The company also intends to pursue studies exploring potential treatments for systemic sclerosis-associated Raynaud’s phenomenon (SSc-RP) and pulmonary hypertension associated with chronic obstructive pulmonary disease. Yutrepia has received Fast Track designation for SSc-RP.
Where Does LQDA Stand?
The settlement with UTHR is a significant development for Liquidia, as it resolves six pending legal disputes and provides uninterrupted patient access to Yutrepia for PAH.
Liquidia Corporation Price, Consensus and EPS Surprise
However, the $380.7 million in payments represents a considerable financial commitment, while the removal of the PH-ILD indication from Yutrepia’s label narrows its current approved use. With the business heavily focused on Yutrepia and future pipeline programs, investors will need to monitor commercial growth, cash generation and clinical execution closely.
The company’s ability to sustain Yutrepia’s momentum while meeting its obligations and advancing its pipeline will be critical to its longer-term prospects.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48.
Corcept Therapeutics’ earnings missed estimates in two of the trailing four quarters, beat in one and met in the other, with the average surprise being 240.74%.
View the Zacks #1 Rank List
Image: Bigstock
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Key Takeaways
Liquidia Corporation (LQDA - Free Report) has reached a global settlement with United Therapeutics (UTHR - Free Report) , resolving all six pending legal disputes between the companies and providing greater clarity on the commercial outlook for Yutrepia.
The agreement ensures uninterrupted access to Yutrepia for patients with pulmonary arterial hypertension (PAH).
The stock is trading up in pre-market trading.
Year to date, LQDA stock has lost 22.3% against the industry’s growth of 1.8%.
Image Source: Zacks Investment Research
However, the settlement comes at a substantial financial cost, with Liquidia agreeing to make net payments of $380.7 million in multiple installments during 2026-2027.
Although the agreement removes a significant source of legal uncertainty, the financial obligations and the removal of the pulmonary hypertension associated with interstitial lung disease (PH-ILD) indication from Yutrepia’s label present challenges for the company.
LQDA Settles All Pending Litigation With UTHR
The settlement follows a Sept. 30, 2026, ruling by the U.S. District Court for the District of Delaware, which found that claims 1 and 14 of UTHR’s U.S. Patent No. 11,826,327 were valid and infringed by Liquidia. The patent claims generally cover the treatment of PH-ILD with inhaled treprostinil, including dry-powder formulations.
Under the agreement, Liquidia has agreed not to appeal the ruling. It has also submitted a supplement to remove the PH-ILD indication from Yutrepia’s label and will discontinue promotion of the drug for this condition.
The settlement resolves six legal matters involving patent infringement, alleged trade secret misappropriation, breach of contract and antitrust violations. The agreement includes mutual releases and does not constitute an admission of liability by either company.
The resolution eliminates the need for Liquidia to continue allocating resources to these disputes, providing greater certainty as it focuses on commercial execution and clinical development.
However, the removal of the PH-ILD indication limits Yutrepia’s current labeled use to PAH, making continued growth in this market particularly important.
Financial Details of LQDA and UTHR Litigation Settlement
Under the settlement terms, Liquidia will make a net payment of $175 million to UTHR within 30 business days. The company will subsequently pay another $145.4 million in two equal installments of $72.7 million, due by Jan. 31, 2027, and April 30, 2027.
In connection with the settlement, Liquidia entered into agreements with the parties with interests in the antitrust litigation related to treprostinil Injection. As per the terms of the agreement, Liquidia will pay an aggregate of $60.3 million this month in full satisfaction of those parties’ interests in the antitrust litigation.
These amounts bring the total settlement-related payments to $380.7 million.
The sizable financial commitment could constrain Liquidia’s financial flexibility in the near term. Nevertheless, management expects to fund the obligations through Yutrepia sales and existing cash reserves while continuing to invest in the business.
LQDA Provides Preliminary Sales
Liquidia has entered the settlement with encouraging commercial momentum. Preliminary, unaudited third-quarter 2026 results showed Yutrepia net product sales of $222.7 million, contributing to cash and cash equivalents of $396.1 million as of Sept. 30, 2026.
Management expects to rebuild its cash position and fund planned clinical studies without requiring additional financing. However, the company's ability to meet its settlement obligations while preserving sufficient resources for commercial expansion and research will be an important factor to monitor.
Liquidia has also terminated its promotional agreement related to treprostinil injection and will no longer commercially support the product.
Pipeline Development Remains a Priority
Beyond Yutrepia, Liquidia plans to continue advancing L606, an investigational extended-release formulation of treprostinil administered twice daily through a next-generation nebulizer. Pivotal studies are planned to support its development for PAH and PH-ILD.
The company also intends to pursue studies exploring potential treatments for systemic sclerosis-associated Raynaud’s phenomenon (SSc-RP) and pulmonary hypertension associated with chronic obstructive pulmonary disease. Yutrepia has received Fast Track designation for SSc-RP.
Where Does LQDA Stand?
The settlement with UTHR is a significant development for Liquidia, as it resolves six pending legal disputes and provides uninterrupted patient access to Yutrepia for PAH.
Liquidia Corporation Price, Consensus and EPS Surprise
Liquidia Corporation price-consensus-eps-surprise-chart | Liquidia Corporation Quote
However, the $380.7 million in payments represents a considerable financial commitment, while the removal of the PH-ILD indication from Yutrepia’s label narrows its current approved use. With the business heavily focused on Yutrepia and future pipeline programs, investors will need to monitor commercial growth, cash generation and clinical execution closely.
The company’s ability to sustain Yutrepia’s momentum while meeting its obligations and advancing its pipeline will be critical to its longer-term prospects.
LQDA’s Zacks Rank and Stocks to Consider
LQDA currently has a Zacks Rank #5 (Strong Sell).
A couple of better-ranked stocks in the pharma/biotech sector are Amarin (AMRN - Free Report) and Corcept Therapeutics (CORT - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48.
Corcept Therapeutics’ earnings missed estimates in two of the trailing four quarters, beat in one and met in the other, with the average surprise being 240.74%.